T Cell News and Research

Latest T Cell News and Research

Cocoa can help prevent onset of colon carcinogenesis

A new study on living animals has shown for the first time that eating cocoa (the raw material in chocolate) can help to prevent intestinal complaints linked to oxidative stress, including colon carcinogenesis onset caused by chemical substances.

24 Jan 2012

Aphios receives NIH's Phase II SBIR grant to develop APH-0703 for AD

Aphios Corporation has received a Phase II SBIR grant from the National Institutes of Health (NIH) amounting to $2.4 million over two years. The National Institute on Aging (NIA), part of the NIH, awarded the grant to the Aphios Corporation to develop an "Alzheimer's Disease Therapeutic."

24 Jan 2012

Cholesterol receptor allows entry of HCV virus into human liver cells

A molecule embedded in the membrane of human liver cells that aids in cholesterol absorption also allows the entry of hepatitis C virus, the first step in hepatitis C infection, according to research at the University of Illinois at Chicago College of Medicine.

24 Jan 2012

Brown fat burns in the cold and could hold key to burning excess fat: Study

Brown fat is something that occurs more in thin people than fat, younger people than older and young women than men. It is brown in color and a new study finds that one form of it, which is turned on in cold climates can burn calories from elsewhere in the body to keep the body warm. Another new study finds that a second form of brown fat can be created from ordinary white fat by exercise.

24 Jan 2012

Experts comment on successful stem cell therapy for blindness

According to a new study published in The Lancet, privately funded and led by UCLA and Advanced Cell Technology researchers, two women suffering a progressive form of blindness have shown improved vision.

24 Jan 2012

Stem cells show promise in treating blindness

A medical breakthrough was reported Monday in the journal The Lancet wherein the results of a therapy using human embryonic stem cells in two legally blind patients was described.

24 Jan 2012

Five scientists named recipients of Damon Runyon-Rachleff Innovation Award for cancer research

The Damon Runyon Cancer Research Foundation announced that five scientists with novel approaches to fighting cancer have been named 2012 recipients of the Damon Runyon-Rachleff Innovation Award.

24 Jan 2012

Methylation also plays a significant role outside the nucleus

The same mechanism that stabilises the DNA in the cell nucleus is also important for the structure and function of vertebrate muscle cells. This has been established by RUB-researchers led by Prof. Dr. Wolfgang Linke (Institute of Physiology) in cooperation with American and German colleagues.

24 Jan 2012

RPB awards $220,000 to SUNY Downstate for eye research

Capping SUNY Downstate Medical Center's growth into a major center for eye research, Research to Prevent Blindness (RPB) has awarded SUNY Downstate a four-year challenge grant of $220,000 to spur the development of advanced research into the causes, treatment, and prevention of blinding diseases. Douglas R. Lazzaro, MD, professor and chair of ophthalmology, is the principal investigator.

24 Jan 2012

miR-375 can predict life threatening head and neck cancers

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center, the University Hospital for Einstein, have found a biomarker in head and neck cancers that can predict whether a patient's tumor will be life threatening.

24 Jan 2012

Chromosome aberrations happen in pairs when it comes to cancer

A healthy genome is characterized by 23 pairs of chromosomes, and even a small change in this structure - such as an extra copy of a single chromosome - can lead to severe physical impairment. So it's no surprise that when it comes to cancer, chromosomal structure is frequently a contributing factor, says Prof. Ron Shamir of the Blavatnik School of Computer Science at Tel Aviv University.

24 Jan 2012

ImmunoCellular initiates enrollment in ICT-107 Phase II trial for GBM in 23 centers

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

24 Jan 2012

CQA derivatives in mate tea kill human colon cancer cells

Could preventing colon cancer be as simple as developing a taste for yerba mate tea? In a recent University of Illinois study, scientists showed that human colon cancer cells die when they are exposed to the approximate number of bioactive compounds present in one cup of this brew, which has long been consumed in South America for its medicinal properties.

24 Jan 2012

Elevated blood lead levels put smokers at higher risk for renal cell carcinoma

Higher than normal levels of lead in the blood may signal a risk two times higher than average of developing renal cell carcinoma in smokers, according to medical researchers.

24 Jan 2012

Targeting a single protein can help fight both breast cancers and leukemias

Targeting a single protein can help fight both breast cancers and leukemias, according to two reports published online on January 23 in the Journal of Experimental Medicine.

24 Jan 2012

Scientists reveal structure of cellular protein degradation machinery

Defective proteins that are not disposed of by the body can cause diseases such as Alzheimer's or Parkinson's. Scientists at the Max Planck Institute (MPI) of Biochemistry recently succeeded in revealing the structure of the cellular protein degradation machinery (26S proteasome) by combining different methods of structural biology.

24 Jan 2012

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE(bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy.

24 Jan 2012

Ikaria receives FDA orphan drug designation for use of iNO in PAH

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the use of inhaled nitric oxide (iNO) with the INOpulse DS drug-delivery system as a combination product for pulmonary arterial hypertension.

23 Jan 2012

Study explains how bacterial biofilms expand to form slimy mats on teeth, surgical instruments

New research at Harvard explains how bacterial biofilms expand to form slimy mats on teeth, pipes, surgical instruments, and crops.

23 Jan 2012

Patient enrollment complete in Enlivex Phase I/II clinical trial for autoimmune diseases

Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that the recruitment of 13 patients for the Enlivex Phase I/II clinical trial has been completed.

23 Jan 2012